GLP-1 and the Gallbladder: Gallstones and Biliary Risk

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary disease. A meta-analysis of 76 randomised trials put the relative risk at 1.37, meaning a 37% increase, with cholelithiasis specifically at 1.27. The absolute numbers are smaller than those percentages sound: roughly 27 additional cases per 10,000 people treated per year. Risk was higher at higher doses, with longer treatment, and when the drugs were used for weight loss rather than diabetes, which points at the speed and size of weight loss as a large part of the mechanism. Rapid weight loss has been a recognised gallstone risk factor for decades, independent of any drug. If you have severe right upper abdominal pain, particularly after a fatty meal, that needs assessment rather than research.

When to get seen

Biliary pain has a recognisable character, and it is worth knowing before you need to.

• Severe pain in the upper right abdomen, often starting after a fatty meal
• Pain radiating to the right shoulder blade or through to the back
• Fever alongside abdominal pain, which suggests infection and needs urgent attention
• Yellowing of the skin or the whites of the eyes, pale stools, or dark urine
• Persistent vomiting with abdominal pain

What the meta-analysis found

The 2022 JAMA Internal Medicine meta-analysis pooled 76 randomised trials and found GLP-1 receptor agonist use associated with an increased risk of gallbladder or biliary disease, relative risk 1.37 with a 95% confidence interval of 1.23 to 1.52. For cholelithiasis, gallstones specifically, the relative risk was 1.27 with a confidence interval of 1.10 to 1.47.

Confidence intervals that sit entirely above 1.0 mean the finding is unlikely to be chance. This is a real association across a large body of randomised evidence, not a signal from spontaneous reports.

Relative risk against absolute risk

A 37% increase sounds alarming until you attach it to a baseline. The meta-analysis estimated the absolute increase at about 27 additional cases per 10,000 persons treated per year.

Both numbers describe the same finding. Which one feels more accurate depends on what you are deciding. For a regulator weighing a class of drugs used by millions, 27 per 10,000 per year is a substantial public health quantity. For one person deciding whether to start treatment, it is a small individual probability that sits alongside the reasons the drug was offered.

Why rapid weight loss causes gallstones anyway

Gallstones form when bile becomes supersaturated with cholesterol and the gallbladder empties incompletely, giving crystals time to nucleate and grow.

Rapid weight loss creates both conditions at once. Mobilising fat sends large amounts of cholesterol into bile, raising saturation. At the same time, eating less often and eating less fat reduces the cholecystokinin signal that tells the gallbladder to contract, so bile sits longer and more concentrated. This has been documented in very low calorie diets and after bariatric surgery long before GLP-1s existed.

So a drug that produces 15% to 20% body weight loss over a year would be expected to raise gallstone incidence even if it had no direct effect on the biliary system at all.

Does the drug add risk beyond the weight loss?

Probably a modest amount. Proposed mechanisms include reduced gallbladder motility and altered bile composition attributable to the drug itself rather than to the weight change, described in a 2025 review of the molecular mechanisms.

That work is characterised as emerging rather than established, and it is worth flagging the difference. The association is solid. The apportionment between drug effect and weight-loss effect is less settled.

The dose, duration and indication gradients in the meta-analysis are consistent with weight-loss magnitude carrying a large share, since the weight-loss indication uses higher doses and produces more loss than the diabetes indication does.

Dose, duration and indication

The meta-analysis found risk higher at higher doses, higher with longer treatment duration, and higher when the drugs were used for weight loss rather than for diabetes.

Those three gradients all move in the same direction and all correlate with total weight lost. None of them tells you to avoid treatment. They tell you what the shape of the risk is, and they are the reason someone losing weight quickly on a high dose might reasonably have a conversation with their prescriber about pace.

What gallbladder pain feels like

Biliary colic is typically a severe, steady pain in the upper right abdomen or just below the breastbone, often beginning within an hour or two of a fatty meal, sometimes radiating to the right shoulder blade. It builds, plateaus, and can last from under an hour to several hours before easing.

It is different in character from the ordinary nausea and fullness common during GLP-1 titration, which is why it is worth being able to distinguish the two. Ordinary drug-related nausea does not usually present as severe localised right upper abdominal pain that radiates.

Severe upper abdominal pain radiating through to the back is a separate concern, because pancreatitis carries its own labelled warning on this drug class. Either way, that pain needs assessment.

If you already have gallstones

Known gallstones are worth mentioning to your prescriber before starting or escalating, so the decision is made with that information rather than around it. Many people with gallstones never develop symptoms, and having them is not automatically a reason to avoid treatment.

Similarly, if you are booked for gallbladder surgery, the perioperative considerations for this drug class apply, which are covered on our page about surgery and anaesthesia.

Not medical advice

This page reports published meta-analysis findings and proposed mechanisms. It is general educational information, not advice about your treatment or your symptoms. If you have abdominal pain now, seek assessment rather than reading further.

The evidence, one row per claim

Sources

1. Association of GLP-1 RA Use With Risk of Gallbladder and Biliary Diseases, JAMA Internal Medicine 2022
2. GLP-1 receptor agonists and gallbladder disease risk: molecular mechanisms and clinical implications (2025)

Keep reading

• GLP-1 and GI Side Effects: Nausea, Constipation and RefluxGI effects are the dominant labelled adverse reactions, inseparable from how the drug works, and concentrated
• GLP-1 and Surgery: What to Tell Your AnaesthetistTell the anaesthetic team you are on this drug. Perioperative guidance changed materially in October 2024, and
• "Ozempic Face": Facial Volume Loss on a GLP-1A weight-loss phenomenon with a drug's name attached. The useful content is why facial fat behaves differently
• GLP-1 Sick Days: Vomiting, Diarrhoea and When to Get HelpThe labelled harm chain is short: GI symptoms, then dehydration, then kidney injury. Interrupting it early is